This invention provides a multivalent immunogenic composition including a soluble portion of a Mycoplasma hyopneumoniae (M. hyo) whole cell preparation; and a porcine circovirus type 2 (PCV2) antigen, wherein the soluble portion of the M. hyo preparation is substantially free of both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin.
1. A method for preparing a multivalent immunogenic composition including a soluble portion of a Mycoplasma hyopneumoniae (M. hyo) whole cell preparation, the method comprising:
i) culturing M. hyo in a suitable media over periods ranging from 18-144 hours;
ii) subsequently inactivating the M. hyo culture;
iii) harvesting the inactivated culture fluid, wherein the inactivated culture fluid comprises an M. hyo whole cell preparation comprising both a soluble liquid fraction and insoluble cellular material;
iv) separating the soluble liquid fraction from the insoluble cellular material;
v) substantially removing both IgG and antigen/immunoglobulin immunocomplexes from the separated soluble liquid fraction to form a soluble portion of the M. hyo whole cell preparation; and
vi) subsequently combining the soluble portion of the M. hyo whole cell preparation with a PCV2 antigen.
2. The method of claim 1 , wherein the M. hyo culture is inactivated by exposing the culture to an inactivation agent.
3. The method of claim 2 , wherein the inactivation agent is binary ethylenimine (BEI).
4. The method of claim 2 , further comprising neutralizing the inactivation agent.
5. The method of claim 1 , wherein the soluble liquid fraction is separated from the insoluble cellular material by a centrifugation step.
6. The method of claim 1 , wherein the soluble liquid fraction is separated from the insoluble cellular material by a filtration step.
7. The method of claim 1 , wherein the soluble liquid fraction is separated from the insoluble cellular material by a precipitation step.
8. The method of claim 1 , wherein the separated soluble liquid fraction is treated with a Protein A or Protein G resin to substantially remove both the IgG and antigen/immunoglobulin immunocomplexes contained in the separated soluble liquid fraction.
9. The method of claim 8 , wherein the separated soluble liquid fraction is treated with a Protein A resin to substantially remove both the IgG and antigen/immunoglobulin immunocomplexes contained in the separated soluble liquid fraction.
10. The method of claim 1 , further comprising admixing the immunogenic composition with an adjuvant.
11. The method of claim 10 , wherein the adjuvant is an oil emulsion comprising a polyoxyethylene-polyoxypropylene block copolymer, squalane, polyoxyethylene sorbitan monooleate and a buffered salt solution (SP-oil).
12. The method of claim 1 , further comprising admixing the immunogenic composition with a pharmaceutically-acceptable carrier.
13. The method of claim 1 , further comprising combining the immunogenic composition with at least one additional porcine antigen.